PK of Firsocostat or Fenofibrate in Hepatic Impairment

Phase 1, open-label trial of firsocostat in Nonalcoholic steatohepatitis (NASH) (8 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 5 more. Started Sep 2016; status: completed.